This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hundt, S. Articles by Brenner, H. Search for Related Content PubMed PubMed Citation Articles by Hundt, S. Articles by Brenner, H. Related Collections Review Epidemiology and Prevention Epidemiology and Prevention: Genetics and Biomarkers Commentary

Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Strasse 20, Heidelberg, Germany

Requests for reprints: Ulrike Haug, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Bergheimer Strasse 20, 69115 Heidelberg, Germany. Phone: 49-6221-54-8134; Fax: 49-6221-54-8142. E-mail: u.haug{at}dkfz.de

Background: Despite different available methods for colorectal cancer (CRC) screening and their proven benefits, morbidity, and mortality of this malignancy are still high, partly due to low compliance with screening. Minimally invasive tests based on the analysis of blood specimens may overcome this problem. The purpose of this review was to give an overview of published studies on blood markers aimed at the early detection of CRC and to summarize their performance characteristics.

Method: The PUBMED database was searched for relevant studies published until June 2006. Only studies with more than 20 cases and more than 20 controls were included. Information on the markers under study, on the underlying study populations, and on performance characteristics was extracted. Special attention was given to performance characteristics by tumor stage.

Results: Overall, 93 studies evaluating 70 different markers were included. Most studies were done on protein markers, but DNA markers and RNA markers were also investigated. Performance characteristics varied widely between different markers, but also between different studies using the same marker. Promising results were reported for some novel assays, e.g., assays based on SELDI-TOF MS or MALDI-TOF MS, for some proteins (e.g., soluble CD26 and bone sialoprotein) and also for some genetic assays (e.g., L6 mRNA), but evidence thus far is restricted to single studies with limited sample size and without further external validation.

Conclusions: Larger prospective studies using study populations representing a screening population are needed to verify promising results. In addition, future studies should pay increased attention to the potential of detecting precursor lesions. (Cancer Epidemiol Biomarkers Prev 2007;16(10):1935–53)

Commentary

Biomarkers for Cancer Risk, Early Detection, and Prognosis: The Validation Conundrum

Dean E. Brenner and Daniel P. Normolle
Cancer Epidemiol. Biomarkers Prev. 2007 16: 1918-1920. [Full Text] [PDF]